Within the PAD population, as the SPM:prostaglandin ratio increased, there were associated decreases in the monocyte markers CD18, CD36, CD163, CD54, and chemokine receptor 2 (Table 6). This evidence concerns the gene ITGB2 and peripheral arterial disease.